Phase II trial of GS 6615 in patients with long QT-3 syndrome.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2014
Price : $35 *
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 24 Jul 2014 Planned initiation date changed to 1 Dec 2014, as reported in a Gilead media release.
- 19 May 2014 This trial is planned to be initiated later in 2014, according to a Gilead Sciences media release.
- 19 May 2014 New trial record